News
PHIO
0.8512
+0.12%
0.0010
Weekly Report: what happened at PHIO last week (1019-1023)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 3d ago
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Newsfile · 10/19 13:53
Weekly Report: what happened at PHIO last week (1012-1016)?
Weekly Report · 10/19 09:50
Phio Pharmaceuticals Advances PH-762 With Commercial-Scale cGMP Batch
TipRanks · 10/13 12:57
Weekly Report: what happened at PHIO last week (1005-1009)?
Weekly Report · 10/12 09:54
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
Newsfile · 10/05 11:00
Weekly Report: what happened at PHIO last week (0928-1002)?
Weekly Report · 10/05 09:53
Phio Pharmaceuticals Expands Equity Incentive Pool at Meeting
TipRanks · 09/28 21:15
Weekly Report: what happened at PHIO last week (0921-0925)?
Weekly Report · 09/28 09:50
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
Newsfile · 09/23 11:00
Weekly Report: what happened at PHIO last week (0914-0918)?
Weekly Report · 09/21 09:50
Phio Advances PH-762 Toward Phase 2b Skin Cancer Trial
TipRanks · 09/14 13:17
Weekly Report: what happened at PHIO last week (0907-0911)?
Weekly Report · 09/14 09:54
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Newsfile · 09/11 13:00
Weekly Report: what happened at PHIO last week (0831-0904)?
Weekly Report · 09/07 09:49
Analysts Conflicted on These Healthcare Names: Phio Pharmaceuticals (PHIO), Ionis Pharmaceuticals (IONS) and Protagonist Therapeutics (PTGX)
TipRanks · 08/31 12:10
Weekly Report: what happened at PHIO last week (0824-0828)?
Weekly Report · 08/31 09:54
Phio Pharmaceuticals Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
Dow Jones · 08/26 12:20
HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target
Benzinga · 08/26 12:10
More
Webull provides a variety of real-time PHIO stock news. You can receive the latest news about Phio Pharmaceuticals Corp through multiple platforms. This information may help you make smarter investment decisions.
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.